LNTH
Price
$54.88
Change
-$0.62 (-1.12%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
3.73B
62 days until earnings call
SXTC
Price
$1.46
Change
-$0.00 (-0.00%)
Updated
Aug 29, 04:49 PM (EDT)
Capitalization
169.4M
Interact to see
Advertisement

LNTH vs SXTC

Header iconLNTH vs SXTC Comparison
Open Charts LNTH vs SXTCBanner chart's image
Lantheus Holdings
Price$54.88
Change-$0.62 (-1.12%)
Volume$39.12K
Capitalization3.73B
China SXT Pharmaceuticals
Price$1.46
Change-$0.00 (-0.00%)
Volume$825
Capitalization169.4M
LNTH vs SXTC Comparison Chart in %
Loading...
LNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LNTH vs. SXTC commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LNTH is a StrongBuy and SXTC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (LNTH: $55.50 vs. SXTC: $1.46)
Brand notoriety: LNTH and SXTC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LNTH: 62% vs. SXTC: 24%
Market capitalization -- LNTH: $3.73B vs. SXTC: $169.4M
LNTH [@Pharmaceuticals: Generic] is valued at $3.73B. SXTC’s [@Pharmaceuticals: Generic] market capitalization is $169.4M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LNTH’s FA Score shows that 0 FA rating(s) are green whileSXTC’s FA Score has 0 green FA rating(s).

  • LNTH’s FA Score: 0 green, 5 red.
  • SXTC’s FA Score: 0 green, 5 red.
According to our system of comparison, LNTH is a better buy in the long-term than SXTC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LNTH’s TA Score shows that 5 TA indicator(s) are bullish while SXTC’s TA Score has 3 bullish TA indicator(s).

  • LNTH’s TA Score: 5 bullish, 3 bearish.
  • SXTC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, LNTH is a better buy in the short-term than SXTC.

Price Growth

LNTH (@Pharmaceuticals: Generic) experienced а -6.19% price change this week, while SXTC (@Pharmaceuticals: Generic) price change was -7.01% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.25%. For the same industry, the average monthly price growth was +68.20%, and the average quarterly price growth was +81.63%.

Reported Earning Dates

LNTH is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LNTH($3.73B) has a higher market cap than SXTC($169M). LNTH has higher P/E ratio than SXTC: LNTH (14.60) vs SXTC (0.01). LNTH YTD gains are higher at: -37.961 vs. SXTC (-64.082). LNTH has higher annual earnings (EBITDA): 457M vs. SXTC (-2.35M). SXTC has less debt than LNTH: SXTC (2.65M) vs LNTH (615M). LNTH has higher revenues than SXTC: LNTH (1.52B) vs SXTC (1.93M).
LNTHSXTCLNTH / SXTC
Capitalization3.73B169M2,209%
EBITDA457M-2.35M-19,438%
Gain YTD-37.961-64.08259%
P/E Ratio14.600.01106,928%
Revenue1.52B1.93M78,890%
Total Cash696MN/A-
Total Debt615M2.65M23,234%
FUNDAMENTALS RATINGS
LNTH vs SXTC: Fundamental Ratings
LNTH
SXTC
OUTLOOK RATING
1..100
5963
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
61100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9165
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LNTH's Valuation (60) in the Medical Specialties industry is in the same range as SXTC (77) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to SXTC’s over the last 12 months.

LNTH's Profit vs Risk Rating (61) in the Medical Specialties industry is somewhat better than the same rating for SXTC (100) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew somewhat faster than SXTC’s over the last 12 months.

LNTH's SMR Rating (100) in the Medical Specialties industry is in the same range as SXTC (100) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to SXTC’s over the last 12 months.

SXTC's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as LNTH (91) in the Medical Specialties industry. This means that SXTC’s stock grew similarly to LNTH’s over the last 12 months.

SXTC's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as LNTH (100) in the Medical Specialties industry. This means that SXTC’s stock grew similarly to LNTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LNTHSXTC
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 15 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
LNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JABNX50.330.18
+0.36%
Janus Henderson Balanced N
LZUOX17.70N/A
N/A
Lazard US Equity Focus Open
MDVYX10.63N/A
N/A
MassMutual Diversified Value Svc
SMDVX18.52N/A
N/A
Hartford Schroders US MidCap Opps A
FWBTX15.04N/A
N/A
Fidelity Advisor Multi-Asset Income C

LNTH and

Correlation & Price change

A.I.dvisor tells us that LNTH and EOLS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LNTH and EOLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LNTH
1D Price
Change %
LNTH100%
-2.36%
EOLS - LNTH
33%
Poorly correlated
-0.79%
ACET - LNTH
32%
Poorly correlated
+0.40%
CRDL - LNTH
28%
Poorly correlated
-2.68%
SNDL - LNTH
26%
Poorly correlated
+6.32%
LFCR - LNTH
24%
Poorly correlated
+1.20%
More

SXTC and

Correlation & Price change

A.I.dvisor tells us that SXTC and SNDL have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SXTC and SNDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SXTC
1D Price
Change %
SXTC100%
-1.35%
SNDL - SXTC
28%
Poorly correlated
+6.32%
AYTU - SXTC
27%
Poorly correlated
-0.86%
CPHI - SXTC
24%
Poorly correlated
+1.43%
LNTH - SXTC
22%
Poorly correlated
-2.36%
EOLS - SXTC
22%
Poorly correlated
-0.79%
More